Biofrontera Investor Relations Material
Latest events
Q2 2024
Biofrontera
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Biofrontera Inc
Access all reports
Biofrontera Inc. is a biopharmaceutical company based in the United States, engaged in the commercialization of pharmaceutical products designed to treat dermatological conditions. The company's focus is on photodynamic therapy (PDT) and topical antibiotics. Biofrontera's product portfolio includes Ameluz, a prescription drug for the treatment of actinic keratosis, a common precancerous skin condition, when used in combination with its BF-RhodoLED lamp. Another product, Xepi, is a topical cream approved for the treatment of impetigo, a bacterial skin infection. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
BFRI
Country
🇺🇸 United States